Alpha Tau (DRTS) announced the completion of enrollment in its ReSTART pivotal trial, a U.S. multicenter study evaluating the efficacy and safety of intratumoral Alpha DaRT for the treatment of patients with recurrent cutaneous squamous cell carcinoma. This is the first U.S. pivotal clinical study of Alpha Tau to have completed enrollment, representing a landmark milestone in the Company’s journey towards potential FDA PMA approval of Alpha DaRT in this indication.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Alpha Tau Completes Enrollment in Pivotal U.S. Skin Cancer Trial for Alpha DaRT
- Alpha Tau to Review Interim Data from First REGAIN Glioblastoma Patients
- Alpha Tau treats first patient with Alpha DaRT in Italy
- Alpha Tau Treats First Italian Pancreatic Cancer Patient With Alpha DaRT in Verona Study
- Alpha Tau to Present Alpha DaRT–Pembrolizumab Head and Neck Cancer Data at AHNS 2026